{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:27:30Z","timestamp":1793978850020,"version":"4.8.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100020771","name":"Natural Science Foundation for Young Scientists of Shanxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020084","name":"Guangzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020084","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119255","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T07:06:54Z","timestamp":1787209614000},"page":"119255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of novel dual-target CDK12\/PARP1 inhibitors for the treatment of triple-negative breast cancer"],"prefix":"10.1016","volume":"319","author":[{"given":"Zhi Jian","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi Wen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao Xu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying qi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Jing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6555-5099","authenticated-orcid":false,"given":"Tie-Gen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejmech.2026.119255_bib1","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment a review, JAMA","volume":"321","author":"Waks","year":"2019","journal-title":"J. Am. Med. Assoc."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119255_bib2","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119255_bib3","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ejmech.2018.01.056","article-title":"Discovery of novel mifepristone derivatives via suppressing KLF5 expression for the treatment of triple-negative breast cancer","volume":"146","author":"Lin","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119255_bib4","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov."},{"issue":"21","key":"10.1016\/j.ejmech.2026.119255_bib5","doi-asserted-by":"crossref","first-page":"9788","DOI":"10.1021\/acs.jmedchem.6b00943","article-title":"From lead to drug candidate: optimization of 3-(phenyl ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives as agents for the treatment of triple negative breast cancer","volume":"59","author":"Zhang","year":"2016","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119255_bib6","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3390\/biomedicines9111512","article-title":"Role of PARP in TNBC: mechanism of inhibition, clinical applications, and resistance","volume":"9","author":"Singh","year":"2021","journal-title":"Biomedicines"},{"issue":"16","key":"10.1016\/j.ejmech.2026.119255_bib7","doi-asserted-by":"crossref","first-page":"12022","DOI":"10.1021\/acs.jmedchem.1c00678","article-title":"Discovery, synthesis, and evaluation of highly selective vascular endothelial growth factor receptor 3 (VEGFR3) inhibitor for the potential treatment of metastatic triple-negative breast cancer","volume":"64","author":"Li","year":"2021","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119255_bib8","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41573-021-00209-1","article-title":"Phosphoinositide 3-kinase inhibitors are finally coming of age","volume":"20","author":"Vanhaesebroeck","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"18","key":"10.1016\/j.ejmech.2026.119255_bib9","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJMra1407390","article-title":"Applying synthetic lethality for the selective targeting of cancer","volume":"371","author":"McLornan","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119255_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OTT.S139336","article-title":"Current status of poly(ADP-ribose) polymerase inhibitors and future directions","volume":"10","author":"Ohmoto","year":"2017","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2026.119255_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.freeradbiomed.2016.11.039","article-title":"Coordination of DNA single strand break repair","volume":"107","author":"Abbotts","year":"2017","journal-title":"Free Radical Biol. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119255_bib12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.yexcr.2014.08.027","article-title":"DNA single-strand break repair","volume":"329","author":"Caldecott","year":"2014","journal-title":"Exp. Cell Res."},{"issue":"9737","key":"10.1016\/j.ejmech.2026.119255_bib13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119255_bib14","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1158\/1535-7163.MCT-06-0552","article-title":"Curtin, preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial","volume":"6","author":"H","year":"2007","journal-title":"Mol. Cancer Therapeut."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119255_bib15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1021\/acs.jmedchem.5b01498","volume":"59","author":"Wang","year":"2016","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119255_bib16","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s40265-021-01552-8","article-title":"Pamiparib: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119255_bib17","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/cas.13947","article-title":"Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials","volume":"110","author":"Wang","year":"2019","journal-title":"Cancer Sci."},{"issue":"20","key":"10.1016\/j.ejmech.2026.119255_bib18","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1021\/jm8001263","article-title":"[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4- fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADPribose) polymerase-1","volume":"51","author":"Menear","year":"2008","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119255_bib19","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1021\/bi902079y","article-title":"Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888","volume":"49","author":"Karlberg","year":"2010","journal-title":"Biochemistry"},{"issue":"9","key":"10.1016\/j.ejmech.2026.119255_bib20","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","article-title":"The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial","volume":"14","author":"Sandhu","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2026.119255_bib21","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","article-title":"Mechanisms of PARP inhibitor sensitivity and resistance","volume":"71","author":"D'Andrea","year":"2018","journal-title":"DNA Repair"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119255_bib22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"issue":"7734","key":"10.1016\/j.ejmech.2026.119255_bib23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41586-018-0758-y","article-title":"CDK12 regulates DNA repair genes by suppressing intronic polyadenylation","volume":"564","author":"Dubbury","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119255_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-09703-y","article-title":"CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation","volume":"10","author":"Krajewska","year":"2019","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119255_bib25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4155\/fmc-2020-0240","article-title":"The promise and current status of CDK12\/13 inhibition for the treatment of cancer","volume":"13","author":"Tadesse","year":"2021","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119255_bib26","doi-asserted-by":"crossref","first-page":"7\/1","DOI":"10.1186\/s13008-017-0033-x","article-title":"The emerging roles of CDK12 in tumorigenesis","volume":"12","author":"Paculova","year":"2017","journal-title":"Cell Div."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119255_bib27","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1101\/gad.231274.113","article-title":"3' end formation of pre-mRNA and phosphorylation of Ser2 on the RNA polymerase II CTD are reciprocally coupled in human cells","volume":"28","author":"Davidson","year":"2014","journal-title":"Genes Dev."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119255_bib28","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/cmdc.201700695","article-title":"Structure-based design of selective noncovalent CDK12 inhibitors","volume":"13","author":"Johannes","year":"2018","journal-title":"ChemMedChem"},{"issue":"17","key":"10.1016\/j.ejmech.2026.119255_bib29","doi-asserted-by":"crossref","first-page":"7710","DOI":"10.1021\/acs.jmedchem.8b00683","article-title":"Discovery of 3- benzyl-1-(trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea derivatives as novel and selective cyclin-dependent kinase 12 (CDK12) inhibitors","volume":"61","author":"Ito","year":"2018","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119255_bib30","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.celrep.2016.10.077","article-title":"CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer","volume":"17","author":"Johnson","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.119255_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108302","article-title":"Discovery of 4-(2- (methylamino)thiazol-5-yl)pyrimidin-2-amine derivatives as novel cyclin-dependent kinase 12 (CDK12) inhibitors for the treatment of esophageal squamous cell carcinoma","volume":"158","author":"Cao","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119255_bib32","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41420-023-01754-x","article-title":"The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma","volume":"9","author":"Houles","year":"2023","journal-title":"Cell Death Discov."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119255_bib33","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nchembio.2166","article-title":"Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors","volume":"12","author":"Zhang","year":"2016","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119255_bib34","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1021\/acsmedchemlett.5c00743","article-title":"Discovery of a selective and potent inhibitor of cyclin-dependent kinase12\/13 employing a noncovalent mechanism","volume":"17","author":"Swyka","year":"2026","journal-title":"ACS Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119255_bib35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.chembiol.2017.11.007","article-title":"Overcoming resistance to the THZ series of covalent transcriptional CDK inhibitors","volume":"25","author":"Gao","year":"2018","journal-title":"Cell Chem. Biol."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119255_bib36","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1021\/acs.jmedchem.4c01616","article-title":"Design, synthesis, and biological evaluation of novel orally available covalent CDK12\/13 dual inhibitors for the treatment of tumors","volume":"68","author":"Lu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119255_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113481","article-title":"Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12\/13 covalent inhibitor with efficacy in ewing sarcoma","volume":"221","author":"Jiang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119255_bib38","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/s41388-022-02210-3","article-title":"SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer","volume":"41","author":"Lin","year":"2022","journal-title":"Oncogene"},{"issue":"13","key":"10.1016\/j.ejmech.2026.119255_bib39","doi-asserted-by":"crossref","first-page":"6708","DOI":"10.1021\/acs.jmedchem.9b01929","article-title":"Discovery of MFH290: a potent and highly selective covalent inhibitor for cyclin-dependent kinase 12\/13","volume":"63","author":"Liu","year":"2020","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119255_bib40","doi-asserted-by":"crossref","first-page":"6718","DOI":"10.1021\/acs.jmedchem.5c00127","article-title":"Discovery of YJZ5118: a potent and highly selective irreversible CDK12\/13 inhibitor with synergistic effects in combination with Akt inhibition","volume":"68","author":"Yang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119255_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117378","article-title":"Discovery of novel imidazo[1,2-b]pyridazine derivatives as potent covalent inhibitors of CDK12\/13","volume":"288","author":"Xia","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119255_bib42","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/jclinpath-2018-205356","article-title":"CDK12: an emerging therapeutic target for cancer","volume":"71","author":"Lui","year":"2018","journal-title":"J. Clin. Pathol."},{"issue":"23","key":"10.1016\/j.ejmech.2026.119255_bib43","doi-asserted-by":"crossref","first-page":"14151","DOI":"10.1021\/acs.jmedchem.0c00766","article-title":"Synthetic lethality through the lens of medicinal chemistry","volume":"63","author":"Myers","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119255_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114012","article-title":"Noncovalent CDK12\/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor","volume":"228","author":"Niu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2026.119255_bib45","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1158\/1078-0432.CCR-23-3785","article-title":"Synthetic lethal targeting of CDK12-deficient prostate cancer with PARP inhibitors","volume":"30","author":"Chou","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119255_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115648","article-title":"Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer","volume":"259","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"W1","key":"10.1016\/j.ejmech.2026.119255_bib47","doi-asserted-by":"crossref","first-page":"W556","DOI":"10.1093\/nar\/gkz430","article-title":"GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis","volume":"47","author":"Tang","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119255_bib48","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.molcel.2015.10.013","article-title":"PARP-1 activation requires local unfolding of an autoinhibitory domain","volume":"60","author":"Dawicki-McKenna","year":"2015","journal-title":"Mol. Cell"},{"issue":"16","key":"10.1016\/j.ejmech.2026.119255_bib49","doi-asserted-by":"crossref","first-page":"11066","DOI":"10.1021\/acs.jmedchem.2c00384","article-title":"Discovery of a highly potent and selective dual PROTAC degrader of CDK12 and CDK13","volume":"65","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2026.119255_bib50","doi-asserted-by":"crossref","first-page":"18247","DOI":"10.1021\/acs.jmedchem.4c01596","article-title":"Discovery of ZLC491 as a potent, selective, and orally bioavailable CDK12\/13 PROTAC degrader","volume":"67","author":"Zhou","year":"2024","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119255_bib51","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.bmcl.2014.03.073","article-title":"Design, syntheses, and characterization of piperazine based chemokine receptor CCR5 antagonists as anti prostate cancer agents","volume":"24","author":"Arnatt","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"12","key":"10.1016\/j.ejmech.2026.119255_bib52","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.1021\/acs.jmedchem.5c01058","article-title":"Design and synthesis of PARP\/CDK6 dual-target inhibitors modulating of Wnt\/\u03b2-catenin signaling pathway for the treatment of BRCA wild-type TNBC","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2026.119255_bib53","doi-asserted-by":"crossref","first-page":"7315","DOI":"10.1021\/acs.joc.6b01035","article-title":"Orthogonal discrimination among functional groups in Ullmann-type C-O and C-N couplings","volume":"81","author":"Rovira","year":"2016","journal-title":"J. Org. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119255_bib54","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1021\/acs.jmedchem.8b01709","article-title":"Design and synthesis of poly(ADP-ribose) polymerase inhibitors: impact of adenosine pocket-binding motif appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on potency and selectivity","volume":"62","author":"Velagapudi","year":"2019","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119255_bib55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/ci100275a","article-title":"Assessing the performance of the MM\/PBSA and MM\/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations","volume":"51","author":"Hou","year":"2011","journal-title":"J. Chem. Inf. Model."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2026.119255_bib56","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bpc.2009.12.007","article-title":"Binding of curcumin with glyoxalase I: molecular docking, molecular dynamics simulations, and kinetics analysis","volume":"147","author":"Liu","year":"2010","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.ejmech.2026.119255_bib57","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/A:1008763014207","article-title":"Combined molecular mechanical and continuum solvent approach (MM-PBSA\/GBSA) to predict ligand binding","volume":"18","author":"Massova","year":"2000","journal-title":"Perspect. Drug. Discov."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:00:54Z","timestamp":1793977254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426007002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":57,"alternative-id":["S0223523426007002"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119255","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel dual-target CDK12\/PARP1 inhibitors for the treatment of triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119255","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119255"}}